NOVALYTELABS
NOVALYTENaltrexone/Bupropion100mg · oral tabletsRESEARCH USE ONLY
In stock COA DOCUMENT SLOT-35%
Metabolic Research

Naltrexone/Bupropion

The active compound in Mysimba® · Contrave®

Dual opioid-antagonist/dopamine-reuptake-inhibitor combination — the compound pair behind Mysimba — studied for reward-pathway appetite regulation.

Weight ManagementAppetite ControlCraving ReductionReward Pathway ModulationEnergy Expenditure
100mg
€199.90€129.90-35%
Limited offer — prices slashed on this compound. Pay with crypto for an extra 10% off.
Research catalogueLaboratory-use positioning
Batch documentationBatch certificate supplied with order
Order trackingFrom payment to dispatch

Product information

CompoundNaltrexone/Bupropion
Presentation100mg oral tablets
Also known asMysimba® · Contrave®
CategoryMetabolic Research
AvailabilityIn stock
Batch COACertificate supplied with order
€199.90€129.9035%

You save €70.00 on this presentationan extra 10% off when you pay with crypto.

VIEW CART

For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use.

Overview

Naltrexone/Bupropion is a fixed-dose combination of two well-characterised molecules: naltrexone (an opioid receptor antagonist) and bupropion (a norepinephrine-dopamine reuptake inhibitor). Marketed as Mysimba/Contrave, this combination exploits the convergence of opioid and dopaminergic reward pathways in appetite regulation. The compounds individually have modest effects on body weight, but their combination produces synergistic appetite suppression through complementary mechanisms in the hypothalamic melanocortin system and mesolimbic reward circuits.

Mechanism of Action

Bupropion stimulates hypothalamic POMC neurons to release α-MSH, which activates MC4R to suppress appetite. However, POMC neurons simultaneously release β-endorphin, which acts as an autoinhibitory feedback via mu-opioid receptors on the same neurons — limiting bupropion's anorectic effect. Naltrexone blocks this mu-opioid autoinhibition, sustaining POMC neuron firing and prolonging α-MSH release. In the mesolimbic reward system, bupropion reduces the reinforcing value of food via dopamine/norepinephrine reuptake inhibition, while naltrexone attenuates hedonic (pleasure-driven) eating by blocking opioid-mediated food reward.

Research Applications

  • Hypothalamic melanocortin system and POMC neuron research
  • Opioid-dopamine reward pathway interaction studies
  • Hedonic vs homeostatic appetite regulation investigation
  • Combination pharmacology and synergistic mechanism research
  • Food reward and craving neuroscience models